HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2015 Financial Statements Continued Notes to the Company Financial Statements Continued 51.
Financial assets Cash and cash equivalents These comprise cash held by the Company and short-term bank deposits with an original maturity of three months or less.
The carrying amount of these assets approximates to their fair value.
Financial liabilities Other payables The Directors consider that the carrying amount of other payables approximates to their fair value.
Short term debt In the previous year, short term debt mainly represented a one year syndicated bridge loan of $225 million which was entered into on 7 July 2014.
The bridge loan has been used to finance the acquisition of Bedford Laboratories note 24.
Due to subsidiaries and sister companies Non-current liabilities 2015 2014 $m $m Hikma Pharmaceuticals LLC 100 Hikma Maple Limited 44 44 Hikma Investment LLC 1 Eurohealth International SARL 3 45 147 Current liabilities 2015 2014 $m $m Hikma Investment LLC 5 15 West-Ward USA 31 Hikma Farmaceutica S. A 2 Thymoorgan GmbH 3 Others 1 42 15 Amounts due to sister company of $42 million 2014: $15 million represent non-interest-bearing loan repayable on demand.
Long-term financial debts A US$500 million with a fair value of $494 million 4.25% Eurobond due April 2020 with the rating of BB Ba1.
The proceeds were used to refinance existing debt and for general corporate purposes.
